Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the new postpartum depression medication Zulresso (brexanolone) with Ob.Gyn News on August 20th, [...]
It has been a few months since Zulresso (brexanolone), the new FDA-approved treatment for postpartum depression, has been available. At our clinic, we have had multiple queries regarding how to obtain treatment with Zulresso. One [...]
On this week’s list, we have multiple articles on the impact of perinatal mood and anxiety disorders on the pregnancy and on the family. While we clearly see an increased interest in identifying women with [...]
Not infrequently we see women who ask about the possibility of oophorectomy (surgical removal of the ovaries) as a means of managing what appears to be a menstrually related mood disorder. While this is an [...]
While we tend to think of sleep deprivation as a postpartum issue, sleep problems are relatively common during pregnancy, with 15% to 80% of women reporting sleep problems during the first trimester and 66% to [...]
According to a report published by the CDC in Morbidity and Mortality Weekly Report (MMWR), the use of stimulant medications for the treatment of attention-deficit/hyperactivity disorder (ADHD)Â by reproductive-age women is on the rise. In [...]
We’d like to remind everybody about the upcoming one day course in Women’s Mental Health we will be offering in Boston on Thursday, October 17th. This is the day preceding the MGH Annual Psychopharmacology Conference [...]
Up to 80% of women experience symptoms as they transition into the menopause, including vasomotor symptoms, sleep disturbance, and depressive symptoms. While hormone replacement therapy and certain medications may be helpful, these interventions may have [...]
We’ve come a long way. Prior to the 1980s, most new mothers had never heard of postpartum depression. Over the last few decades we have made considerable progress in educating women about their risk for [...]
Brexanolone, marketed by Sage Therapeutics as Zulresso, was approved in March 2019, as a treatment for postpartum depression. It has been available for almost two months, and we are very eager to hear about patients’ [...]
